Lassogen
San Diego, US · Founded 2019 · Delaware corporation · 3 known investors
Lassogen engineers lasso peptides as therapeutic scaffolds to create Lassotides, a new drug modality combining advantages of antibodies and small molecules for challenging diseases.
Founders & leadership
MJ
Mark J BurkExecutive Officer
Investors · 3
Competitors · 10
by search overlapDiabetes Prevention Program6 shared keywords
Dervan et al4 shared keywords
Rsc4 shared keywords
Frontiersin4 shared keywordsFrontiers is an academic publisher of open-access, community-run journals covering more than 1,700 scientific disciplines, offering researchers tools to submit, publish, and share their work. It also runs Research Topics, a data management service for AI-ready publications, and a science film series for researchers and the broader scientific community.
ResearchGate4 shared keywords
More about Versogen3 shared keywordsVersogen develops electrolyzer systems that produce green hydrogen from water and renewable energy, using patented anion exchange membranes (AEM) and earth-abundant materials. The technology targets industrial applications seeking to reduce carbon emissions.
Mapquest3 shared keywordsProvider of geographical information systems and services; acquired by America Online.
Solugen3 shared keywordsSolugen develops a biomanufacturing platform using fermentation and bioprocessing technology to produce specialty chemicals at scale. The company serves customers in energy, chemicals, and related industries with cost-effective alternatives to traditional petrochemical-based manufacturing.
Popek and Goldberg3 shared keywordsPrinceton is a university whose faculty conduct scholarly research and teach, working closely with undergraduates on junior independent work and senior theses.
Solid Biosciences3 shared keywordsSolid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.
Companies competing with Lassogen for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements▶$5.1MraisedSep 2020 · 16 investors · BiotechnologyRule 506(b)
▶$5.1MraisedSep 2020 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark J BurkExecutive Officer
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $399.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2020 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
- Lassogen Raises Seed Round to Develop Novel Therapeutics for Challenging Targetsbusinesswire.com · 2020
- Lassogen Raises $4.5M in Seed Funding - FinSMEsfinsmes.com · 2020
- The Crunchbase News Briefing: Tue., Oct. 13news.crunchbase.com · 2020
- TCT Exclusive: Dakota McKenzie, GTM @ Unusual Venturessacra.com